Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

The document concludes that a systematic approach is crucial to identify causes of androgen excess in women beyond the most common cause, Polycystic ovary syndrome (PCOS).

PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.

Treatment with dutasteride, minoxidil, and artificial hair transplantation improved appearance but caused folliculitis.

Women with PCOS may have a higher risk of respiratory and ear infections due to slower nasal mucociliary clearance.

A woman's hair loss was caused by her husband's testosterone gel and a diabetic man's nail disease led to bone infection, both treated successfully.

Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.

About 8.5% of women in Salvador, Brazil, have Polycystic Ovary Syndrome.

Menopause significantly reduces skin collagen, leading to thinner, less elastic skin, and hormone replacement may help but requires careful consideration.

Stress, hypothyroidism, drug intake, and anemia are important factors in women's diffuse hair loss.

Testosterone therapy may improve mood, well-being, and sexual function in premenopausal women, but more research is needed on its long-term safety and effectiveness.

A teenage girl had both a rare ovarian tumor and a severe form of polycystic ovarian syndrome.

Taking 5 mg/day finasteride can cause side effects in women with hair loss, but these are usually mild and fade over time, making the treatment beneficial in the long run.

DNA methylation changes in women with PCOS could be used as disease markers and suggest new treatment targets.

Finasteride 5 mg and topical minoxidil 5% effectively increase hair density in women, with finasteride 5 mg having the highest satisfaction.

Bicalutamide may help treat female pattern hair loss.

Over 50% of women over 50 experience hair loss, with minoxidil being the only proven effective treatment.

Hormones might affect the skin condition hidradenitis suppurativa, but their exact role is unclear.

Women with androgenetic alopecia (hair loss) have normal prostate specific antigen levels but higher testosterone levels.

Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.

FAGA diagnosis uses blood tests and trichoscopy, with treatments like topical minoxidil, oral anti-androgens, and hormone-modulating drugs.

FPHL causes hair loss in women due to genetics and hormones; minoxidil and anti-androgens are treatments, and early intervention is advised.

Different types of female pattern hair loss have unique characteristics and are associated with various health conditions.

Female pattern hair loss is different from male pattern hair loss and has unclear genetic causes.

Some treatments for hair loss, like finasteride, biotin, and minoxidil, can be effective, but their success varies by individual case.

The document concludes that there are no reliable treatments for frontal fibrosing alopecia, with only temporary benefits from current options.

Certain metabolites are lower in women with PCOS and could be potential markers for the condition.

This text talks about how to treat hair loss in women. It suggests different options and stresses the importance of support.

Antiandrogens are the main treatment for hirsutism, with individualized care and safe, affordable options needed.

Hair loss in women not always linked to increased oil production; other factors may be involved.